BR9914901A - Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca - Google Patents

Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca

Info

Publication number
BR9914901A
BR9914901A BR9914901-0A BR9914901A BR9914901A BR 9914901 A BR9914901 A BR 9914901A BR 9914901 A BR9914901 A BR 9914901A BR 9914901 A BR9914901 A BR 9914901A
Authority
BR
Brazil
Prior art keywords
metoclopramide
migraine
treatment
receptor agonists
mammal
Prior art date
Application number
BR9914901-0A
Other languages
English (en)
Inventor
George Harry Sands
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9914901A publication Critical patent/BR9914901A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Patente de Invenção: <B>''AGONISTAS DO RECEPTOR 5HT~ 1~ E METOCLOPRAMIDA PARA O TRATAMENTO DE ENXAQUECA''<D>. A presente invenção relaciona-se com um método de tratamento de enxaqueca em um mamífero, incluindo o ser humano, por administração ao mamífero de um agonista do receptor 5HT~ 1~, e particularmente eletriptano, em combinação com metoclopramida. Também se relaciona com composições farmacêuticas contendo um veículo farmaceuticamente aceitável, um agonista de receptor 5HT~ 1~, e metoclopramida.
BR9914901-0A 1998-10-30 1999-10-18 Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca BR9914901A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30
PCT/IB1999/001694 WO2000025778A1 (en) 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Publications (1)

Publication Number Publication Date
BR9914901A true BR9914901A (pt) 2001-07-17

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914901-0A BR9914901A (pt) 1998-10-30 1999-10-18 Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca

Country Status (34)

Country Link
US (2) US6255334B1 (pt)
EP (1) EP1126840A1 (pt)
JP (1) JP2002528497A (pt)
KR (1) KR20010089363A (pt)
CN (1) CN1325304A (pt)
AP (1) AP2001002129A0 (pt)
AR (1) AR019246A1 (pt)
AU (1) AU5994799A (pt)
BG (1) BG105534A (pt)
BR (1) BR9914901A (pt)
CA (1) CA2348543A1 (pt)
CO (1) CO4950530A1 (pt)
CZ (1) CZ20011468A3 (pt)
EA (1) EA200100284A1 (pt)
EE (1) EE200100243A (pt)
GT (1) GT199900189A (pt)
HK (1) HK1040929A1 (pt)
HR (1) HRP20010298A2 (pt)
HU (1) HUP0104696A3 (pt)
ID (1) ID28291A (pt)
IL (1) IL141957A0 (pt)
IS (1) IS5898A (pt)
MA (1) MA26702A1 (pt)
NO (1) NO20012013D0 (pt)
OA (1) OA11669A (pt)
PA (1) PA8484801A1 (pt)
PE (1) PE20001284A1 (pt)
PL (1) PL347541A1 (pt)
SK (1) SK5522001A3 (pt)
TN (1) TNSN99203A1 (pt)
TR (1) TR200101174T2 (pt)
TW (1) TW524692B (pt)
WO (1) WO2000025778A1 (pt)
ZA (1) ZA200103322B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
WO2002094218A2 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
CA2507159A1 (en) 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
AR060451A1 (es) * 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
IL127956A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
ID28291A (id) 2001-05-10
OA11669A (en) 2005-01-05
AU5994799A (en) 2000-05-22
TNSN99203A1 (fr) 2005-11-10
EP1126840A1 (en) 2001-08-29
AP2001002129A0 (en) 2001-06-30
JP2002528497A (ja) 2002-09-03
PA8484801A1 (es) 2000-09-29
ZA200103322B (en) 2002-06-10
HRP20010298A2 (en) 2002-06-30
CN1325304A (zh) 2001-12-05
NO20012013L (no) 2001-04-24
SK5522001A3 (en) 2002-05-09
US6255334B1 (en) 2001-07-03
WO2000025778A1 (en) 2000-05-11
IL141957A0 (en) 2002-03-10
AR019246A1 (es) 2001-12-26
CZ20011468A3 (cs) 2002-04-17
GT199900189A (es) 2001-04-21
TW524692B (en) 2003-03-21
EA200100284A1 (ru) 2001-10-22
TR200101174T2 (tr) 2001-10-22
US20010020036A1 (en) 2001-09-06
IS5898A (is) 2001-03-16
CO4950530A1 (es) 2000-09-01
CA2348543A1 (en) 2000-05-11
HUP0104696A3 (en) 2003-05-28
HK1040929A1 (zh) 2002-06-28
EE200100243A (et) 2002-12-16
PL347541A1 (en) 2002-04-08
PE20001284A1 (es) 2000-11-22
MA26702A1 (fr) 2004-12-20
BG105534A (en) 2001-12-29
KR20010089363A (ko) 2001-10-06
NO20012013D0 (no) 2001-04-24
HUP0104696A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
BR0110420A (pt) Agonistas muscarìnicos
BR9814923A (pt) Método para tratamento de doença de alzheimer
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
BR9811780A (pt) Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
EA200101089A1 (ru) Новый способ лечения
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
BR0200246A (pt) Tratamento de combinação para a depressão
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BR0103913A (pt) Tratamento de combinação para depressão e ansiedade
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
BR9913348A (pt) Tratamento dos distúrbios da ansiedade
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1919 DE 16/10/2007.